Overcoming Disparity with Novelty in Triple-Negative Breast Cancer: Community Oncology Perspectives on Promoting Equity and Improving Clinical Outcomes

February 24, 2022

Target Audience

Community oncologists and their interprofessional care team of nurse practitioners, nurses, pharmacists, and physician assistants who manage patients with triple-negative breast cancer (TNBC), specifically those practicing in the southeastern United States.

Learning Objectives

  • Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable care and outcomes for all patients.
  • Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, including dosing, administration, and toxicity management, for community oncology clinicians using ADCs to manage TNBC. 
  • Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
  • Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus and the effective integration of socioeconomic and other non-biologic factors into equitable cancer care.   
     

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 IPCE
  • 1.00 Participation
Course opens: 
02/23/2022
Course expires: 
04/30/2022
Event starts: 
02/24/2022 - 6:00pm EST
Event ends: 
02/24/2022 - 7:00pm EST
Rating: 
5
Virtual GR Community
United States

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, Illinois

 


It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners:
Allison Butts, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Lauren Olalde, RN– has disclosed that she is on the speakers' bureau for Trodelvy.

Planners/Presenters:
Rita Nanda, MD–has disclosed that she is a consultant for Cardinal Health, Clovis, Fujifilm, G1 Therapeutics, Genentech, Immunomedics/Gilead, iTeos, MacroGenics, Merck, Oncosec, Pfizer, and Seattle Genetics. She receives grant/research support from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, and Taiho.
Sara Tolaney, MD, MPH– has disclosed that she is a consultant for 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, BeyondSpring Pharmaceuticals, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Immunomedics/Gilead, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Puma, Sanofi, and Seattle Genetics. She receives grant/research funding from Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics.

Peer Reviewers:
Susan H. Gitzinger, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Jennifer McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-21-015-L01-P)

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 IPCE
  • 1.00 Participation
Please login or register to take this course.